Literature DB >> 21222505

Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom.

Lia Gutiérrez1, Neil Roskell, Jordi Castellsague, Stephen Beard, Catherine Rycroft, Shaun Abeysinghe, Paul Shannon, Sean Robbins, Matthew Gitlin.   

Abstract

OBJECTIVE: To determine the incremental cost of healthcare and clinical outcomes in the 12 months following incident hip fractures among postmenopausal women in the UK.
METHODS: Retrospective cohort study of women aged 50 years or older hospitalized for an incident hip fracture within 1 week of the fracture date who were age- and comorbidity-matched to women without fracture. Cohorts were identified in the Health Improvement Network database, and followed up for 1 year.
RESULTS: Among 2,427 women who had a hip fracture and a recorded hospitalization, the mean [SD] age was 81 [9.3] years. About 18% of women without fractures were hospitalized during follow-up and 18% of women with hip fractures and 4% of women without fractures had at least one emergency admission (RR, 4.7; 95% CI, 3.8-5.8). There were no major differences in use of general practitioner visit, referral visits, or in prescription of medications. Mortality was 18% in the hip fracture cohort and 7% in the non-fracture cohort (RR, 2.5; 95% CI, 2.1-3.0). The overall 1-year mean incremental cost of hip fractures was £4,222 (95% CI, £4,105-4,339); most of this cost (97%) was for hospitalizations, with an increment of £4,095. About 98% of the incremental cost occurred in the first 6 months following hip fracture.
CONCLUSIONS: The results of this study indicate that the cost and clinical burden associated with hip fractures in postmenopausal women in the UK are considerable. The incremental cost is mostly related to the cost of hospitalization and treatment of the hip fracture. Key limitations were the inclusion of only those women with a recorded hospitalization, and that costs associated with rehabilitation services, social services, and long-term care were not recorded in this study, although these are important contributors to the total cost of fractures.

Entities:  

Mesh:

Year:  2011        PMID: 21222505     DOI: 10.3111/13696998.2010.547967

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  12 in total

1.  The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study.

Authors:  Alexis Ogdie; Lauren Harter; Daniel Shin; Joshua Baker; Junko Takeshita; Hyon K Choi; Thorvardur Jon Love; Joel M Gelfand
Journal:  Ann Rheum Dis       Date:  2017-01-16       Impact factor: 19.103

2.  Risk of fracture in urolithiasis: a population-based cohort study using the health improvement network.

Authors:  Michelle R Denburg; Mary B Leonard; Kevin Haynes; Shamir Tuchman; Gregory Tasian; Justine Shults; Lawrence Copelovitch
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

3.  Assessment of Sex Differences in Fracture Risk Among Patients With Anorexia Nervosa: A Population-Based Cohort Study Using The Health Improvement Network.

Authors:  Jason M Nagata; Neville H Golden; Mary B Leonard; Lawrence Copelovitch; Michelle R Denburg
Journal:  J Bone Miner Res       Date:  2017-01-19       Impact factor: 6.741

4.  Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

Authors:  Sarah Davis; Emma Simpson; Jean Hamilton; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong; Edward Goka; Neil Gittoes; Peter Selby
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

5.  Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.

Authors:  E Söreskog; F Borgström; L Shepstone; S Clarke; C Cooper; I Harvey; N C Harvey; A Howe; H Johansson; T Marshall; T W O'Neill; T J Peters; N M Redmond; D Turner; R Holland; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2020-04-01       Impact factor: 4.507

6.  A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.

Authors:  E Söreskog; F Borgström; I Lindberg; O Ström; D Willems; C Libanati; J A Kanis; B Stollenwerk; M Charokopou
Journal:  Osteoporos Int       Date:  2021-01-07       Impact factor: 4.507

7.  Burden of First Osteoporotic Hip Fracture in Spain: A Prospective, 12-Month, Observational Study.

Authors:  Jose Ramón Caeiro; Agustí Bartra; Manuel Mesa-Ramos; Íñigo Etxebarría; Jorge Montejo; Pedro Carpintero; Francesc Sorio; Sonia Gatell; Andrea Farré; Laura Canals
Journal:  Calcif Tissue Int       Date:  2016-10-14       Impact factor: 4.333

8.  A health economic analysis of osteoporotic fractures: who carries the burden?

Authors:  Louise Hansen; Anne Sofie Mathiesen; Peter Vestergaard; Lars H Ehlers; Karin D Petersen
Journal:  Arch Osteoporos       Date:  2013-02-19       Impact factor: 2.617

9.  An exploration of barriers and facilitators to older adults' participation in higher impact physical activity and bone health: a qualitative study.

Authors:  B A J Simmonds; K J Hannam; K R Fox; J H Tobias
Journal:  Osteoporos Int       Date:  2015-11-10       Impact factor: 4.507

10.  Impact of hip fracture on hospital care costs: a population-based study.

Authors:  J Leal; A M Gray; D Prieto-Alhambra; N K Arden; C Cooper; M K Javaid; A Judge
Journal:  Osteoporos Int       Date:  2015-08-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.